Clinical trial · Interventional
Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation
NCT03423706CI-TRIAL-00042390unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Building a new haploid transplanted model with high-dose CTX、CD19-CART,donor CD34+ hematopoietic stem cell and Tregs,to prevent graft-versus-host disease(GVHD),reduce the infection,promote the rate of immune reconstruction，seperate graft versus leukemia（GVL）and GVHD，then to reduce the relapse rate after hematopoietic stem cell transplantation（HSCT）for relapsed and/or refractory B cell acute lymphoblastic leukemia（r/r-B-ALL）.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CD19-chimeric Antigen Receptor T Cells | — | UNRESOLVED | — |
| Relapsed and/or Refractory Acute Lymphoblastic Leukemia | — | UNRESOLVED | — |
| the Haploidentical Hematopoietic Stem Cell Transplantation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| the new model of haplo-HSCT for r/r B-ALL | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- new model of haplo-HSCT
- description
- use the new model of haplo-HSCT to treat the r/r B-ALL patients matching the inclusion criterion
- interventionNames
- Procedure: the new model of haplo-HSCT for r/r B-ALL
Primary outcomes (2)
- measure
- disease free survival at six months
- timeFrame
- six months
- description
- the disease free survival of the new model haplo-HSCT will be assessed at 6 months.
- measure
- acute graft-versus-host disease
- timeFrame
- three months
- description
- we will examine the treatment-related acute GVHD at 3 months.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. the r/r B-ALL patients 2. have the healthy allo-HSCT donor 3. voluntary and signed the treatment protocol Exclusion Criteria: 1. not match the inclusion criteria 2. important organ is dysfunction, such as heart and/or renal dysfunction,liver failure 3. Pregnancy or breast-feeding women 4. has virus infection,such as HIV,hepatitis virus,and can not be cleared with anti-virus treatment
References
Publications (0)
Data not yet available
No reference posted for this study.